Lymphocyte Therapy in Treating Patients With Kidney Cancer

NCT00002589 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

NIH

Sponsor class

Conditions

Kidney Cancer

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: muromonab-CD3
BIOLOGICAL: therapeutic autologous lymphocytes
PROCEDURE: adjuvant therapy

Sponsor

National Cancer Institute (NCI)